News
Clinical data from the OT-101 P001 PDAC study suggest that targeting TGFB2 merits additional evaluation in younger patients; in a treated subset characterized by low IL-6, median OS was 12.7 months. † ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results